Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 5/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL74107 | 1.00 | RIPK1 (0.38) | RIPK1TNFNPSR1GAA | |
| SCHEMBL75836 | 0.78 | LMNA (0.40) | — | |
| SCHEMBL75835 | 0.78 | LMNA (0.40) | — | |
| SCHEMBL15026061 | 0.77 | ALDH1A1 (0.41) | RIPK1TNFNPSR1GAA | |
| SCHEMBL14687910 | 0.77 | ALDH1A1 (0.41) | RIPK1TNFNPSR1GAA | |
| SCHEMBL16001119 | 0.73 | RIPK1 (0.42) | RIPK1TNFNPSR1GAA | |
| SCHEMBL1362696 | 0.73 | RIPK1 (0.42) | RIPK1TNFNPSR1GAA | |
| SCHEMBL25404225 | 0.71 | RIPK1 (0.38) | RIPK1TNFNPSR1GAA | |
| SCHEMBL12049657 | 0.71 | NPSR1 (0.41) | RIPK1TNFNPSR1GAA | |
| SCHEMBL13799221 | 0.71 | RIPK1 (0.38) | RIPK1TNFNPSR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129412-B2 | Hydantoin derivatives useful as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| EP-1828166-B1 | HYDANTOIN DERIVATIVES USEFUL AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | EP | disclosed |
| US-20080280950-A1 | Hydantoin Derivatives Useful as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| EP-1828166-A1 | HYDANTOIN DERIVATIVES USEFUL AS METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006064218-A1 | HYDANTOIN DERIVATIVES USEFUL AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280950-A1 | Hydantoin Derivatives Useful as Metalloproteinase Inhibitors | MMP3, MMP9, MMP2 | RIPK1 3831/4885TNF 4286/4885NPSR1 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.